Curaleaf (OTCMKTS:CURLF) Shares Up 11.4% – Still a Buy?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) shot up 11.4% during trading on Tuesday . The company traded as high as $2.46 and last traded at $2.45. 225,577 shares traded hands during trading, a decline of 60% from the average session volume of 566,712 shares. The stock had previously closed at $2.20.

Wall Street Analysts Forecast Growth

CURLF has been the subject of a number of analyst reports. ATB Cormark Capital Markets raised shares of Curaleaf to an “outperform” rating in a research note on Tuesday, December 2nd. Zacks Research upgraded Curaleaf from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Alliance Global Partners restated a “buy” rating on shares of Curaleaf in a research report on Monday, December 22nd. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

Curaleaf Trading Down 1.9%

The stock has a market cap of $1.65 billion, a P/E ratio of -7.60 and a beta of 0.74. The stock’s 50-day moving average is $2.53 and its two-hundred day moving average is $2.71. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.47 and a quick ratio of 0.71.

Curaleaf (OTCMKTS:CURLF) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. Curaleaf had a negative net margin of 19.50% and a negative return on equity of 15.57%. Equities research analysts anticipate that Curaleaf Holdings, Inc. will post -0.25 EPS for the current year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.